Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC
Read More
Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC
Read More
CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib
Read More
Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC
Read More
Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC
Read More
Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC
February 14th 2020Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.
Read More
Dr. Pal Compares CheckMate-214 and CABOSUN Trials in RCC
September 13th 2017Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses both the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).
Read More